– Four posters highlight TERLIVAZ research on the potential impact of dosing and outcomes in key subpopulations of adults with HRS with rapid reduction in kidney function 1 – DUBLIN , Oct. 30, 2024 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced the presentation of four posters on TERLIVAZ ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function 1 at The Liver Meeting , the annual meeting of the American Association for the Study of Liver Diseases (AASLD) taking place in San Diego from November 15-19, 2024 . TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function, 1 an acute and life-threatening condition requiring hospitalization.
2 HRS involving rapid reduction in kidney function 1 is estimated to affect more than 42,000 Americans annually, approximately 0.01% of the U.S.
population, 3 making it a very rare condition; and rates of hospitalizations are increasing. 4 Please see Limitation of Use and Important Safety Information, including Boxed Warning, below. Three posters include pooled data from Phase 3 placebo-controlled studies with TERLIVAZ, examining the potential impact of waiting until Day 4 and after 12 doses before assessing HRS reversal; the effect of obesity, as measured by body mass index (BMI), on HRS reversal; and HRS reversal in patients treated with the standar.
